Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2408 • 2017 ACR/ARHP Annual Meeting
Early Frailty Syndrome in Rhematoid Arthitis: Screening Using the Frail Scale
Elisa Trujillo^1,2 and Maria del Mar Trujillo³, ¹Rheumatology, Hospital Universitario de Canarias, La Laguna.Tenerife, Spain, ²Hospital Universitario de Canarias, Servicio de Reumatologia, Tenerife, Spain, ³Servicio de Evaluación y Planificación, Fundación Canaria de Investigación Sanitaria (FUNCANIS) Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Santa cruz de Tenerife, Spain
Background/Purpose: Frailty is defined as a syndrome of physiological decline in late life, characterized by marked vulnerability to adverse health outcomes. Frail adults are less…
Abstract Number: 124 • 2017 ACR/ARHP Annual Meeting
Smoking and Rheumatoid Arthritis Susceptibility; Quantification of the Impact of Cumulative Dose, Frequency and Duration of Smoking, and Smoking Cessation
Lars Alfredsson¹, Anna Karin Hedström², Camilla Bengtsson³ and Lars Klareskog⁴, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Smoking is one of the most established risk factors for rheumatoid arthritis (RA). The aim of this study was to estimate how age at…
Abstract Number: 490 • 2017 ACR/ARHP Annual Meeting
Clinical and Biomarker Factors in the Prediction of Future Inflammatory Arthritis in ACPA Positive Subjects without Inflammatory Arthritis at Baseline
John P. Gerstenberger¹, Colin I. O'Donnell², Sarah L. Dill³, Randall Tagg⁴, Masoud Asadi-Zeydabadi⁴, M. Kristen Demoruelle⁵, V. Michael Holers⁶ and Kevin D. Deane⁷, ¹Department of Medicine, University of Colorado Denver School of Medicine, Aurora, CO, ²University of Colorado Denver School of Medicine, Aurora, CO, ³Division of Rheumatology, University of Colorado Denver School of Medicine, Aurora, CO, ⁴Department of Physics, University of Colorado Denver, Denver, CO, ⁵1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁶Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Antibodies to citrullinated protein antigens (ACPA) can identify individuals who may develop future inflammatory arthritis (IA) and classifiable rheumatoid arthritis (RA). Indeed, there are…
Abstract Number: 1407 • 2017 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is an arthritis severity and joint damage gene recently discovered in rodent models of arthritis. Hip1 regulates fibroblast-like synoviocytes (FLS)…
Abstract Number: 2457 • 2017 ACR/ARHP Annual Meeting
Sarilumab for the Treatment of Active, Moderate-to-Severe Rheumatoid Arthritis (RA): An Analysis of Cost per Effectively Treated Patient
Marie Fournier¹, Chieh-I Chen², Andreas Kuznik², Clare Proudfoot³, Usha Mallya⁴ and Kaleb Michaud⁵, ¹Sanofi France, Chilly-Mazarin, France, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Formerly of Sanofi, Guildford, United Kingdom, ⁴Sanofi, Bridgewater, NJ, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The MONARCH study (NCT02332590) evaluated monotherapy with sarilumab 200 mg subcutaneous (SC) + placebo every 2 weeks (Q2W) versus adalimumab 40 mg SC +…
Abstract Number: 561 • 2016 ACR/ARHP Annual Meeting
Sodium Intake Is Increased in Patients with Early Rheumatoid Arthritis and Is Associated with Radiographic Erosions
sarah marouen¹, Guilhem du Cailar², Rachel Audo³, Cédric Lukas⁴, Gaelle Vial⁵, Anne Tournadre⁶, Emmanuel Barrat⁷, Jean Ribstein², Bernard Combe⁸, Jacques Morel⁹ and Claire I. Daien¹⁰, ¹Rhumatology Department, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ³Rheumatology, Teaching Hospital of Lapeyronie, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology, Gabriel Montpied Hospital and Clermont Ferrand University, Clermont Ferrand, France, ⁶Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Recherche et Développement, Laboratoire Lescuyer, AYTRE, France, ⁸Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁹Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ¹⁰Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease resulting from an interaction between genetic and environmental factors. Recently, sodium intake was suggested as a risk…
Abstract Number: 1582 • 2016 ACR/ARHP Annual Meeting
Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
Alan Slade¹, Phillip Koo¹, Yanling He², Pascal Espie³, Anita Auger-Sarrazin³, James S. Rush³ and Peter Gergely³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Novartis Pharmaceuticals Corporation, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, Basel, Switzerland
Background/Purpose: Aberrant CD40-CD154 pathway signaling has been linked to pathology in autoimmune disease. Blocking the CD40-CD154 pathway prevents T cell-dependent antibody responses, germinal center formation…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 577 • 2016 ACR/ARHP Annual Meeting
TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells
Naonori Hashimoto¹, Kohsuke Yoshida¹, Teppei Hashimoto², Ayako Nakai¹, Kenta Kaneshiro¹, Kohjin Suzuki¹, Yoshiko Kawasaki², Nao Shibanuma³, Natsuko Nakagawa⁴, Yoshitada Sakai⁵ and Akira Hashiramoto⁶, ¹Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, ³Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁴Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, ⁵Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: DNA is fragmented and released into blood circulation as a circulating cell-free DNA (ccfDNA) because of damage or death of cells. Although the…
Abstract Number: 1593 • 2016 ACR/ARHP Annual Meeting
Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Natalia V. Zamora¹, Jean Tayar², Maria A. Lopez-Olivo³, Robin Christensen⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁵Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Baricitinib is a small molecule inhibitor of the Janus kinase (JAK) pathways that reduce and modulate the production of inflammatory mediators and cytokines. We…
Abstract Number: 2509 • 2016 ACR/ARHP Annual Meeting
Implementation of the Treat to Target Concept in Evaluation of Rheumatoid Arthritis Patients
Devy Zisman^1,2, Shirly Oren³, T. Reitblat⁴, Merav Lidar⁵, Alexandra Balbir-Gurman⁶, Itzhak A. Rosner⁷, Joy Feld², Nimer Halabi⁸, Sameer Kassem⁸ and Ori Elkayam⁹, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁴Barzilai Medical Center, Ashkelon, Israel, ⁵Medicine F, Sheba Medical Center, Ramat Gan, Israel, ⁶B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁷Bnai Zion Medical Center, Haifa, Israel, ⁸Internal Medicine, Carmel Medical Center, Haifa, Israel, ⁹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: To assess the implementation of the treat to target (T2T) concept in rheumatoid arthritis (RA) patients. Methods: Academic rheumatology units were invited to participate…
Abstract Number: 617 • 2016 ACR/ARHP Annual Meeting
Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs
Maria A. Lopez-Olivo¹, Aliza Matusevich^2,3 and Maria Suarez-Almazor⁴, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The University of Texas, School of Public Health, Houston, TX, ⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Up to one-third of the patients who receive TNFi lose responsiveness over time. Options available to these patients include treatment with an alternative TNFi…
Abstract Number: 1602 • 2016 ACR/ARHP Annual Meeting
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
Janet Pope¹, Edward Keystone², Shahin Jamal³, Lisy Wang⁴, Lara Fallon⁵, John Woolcott⁵, Irina Lazariciu⁶ and Boulos Haraoui⁷, ¹Western University, London, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Canada, Montreal, QC, Canada, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Open-label, long-term extension (LTE) studies enrolled tofacitinib-treated patients (pts) to evaluate safety and…
Abstract Number: 2517 • 2016 ACR/ARHP Annual Meeting
Long-Term Stability of the 5-Item Compliance Questionnaire Rheumatology As a Measure of Adherence in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Mary Bell², Charles H. Goldsmith³, Imy Chiu⁴, Anna Gutlin⁴ and Sharron Sandhu⁵, ¹Division of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Simon Fraser University, Vancouver, BC, Canada, ⁴Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for optimal monitoring…
Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].